quinazolines has been researched along with epirubicin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Armand, JP; Evans, TR; Seymour, L | 1 |
| Anthony, DA; Eatock, MM; El-Abassi, M; Evans, TR; Paul, J; Smith, M; Soukop, M; Wilson, P | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
| Amoroso, V; Ferrari, VD; Fusi, A; Mambrini, A; Marini, G; Marpicati, P; Montini, E; Rangoni, G; Simoncini, E; Valcamonico, F; Vasalli, L | 1 |
| Amici, S; Gasparini, G; Gattuso, D; Gion, M; Longo, R; Sarmiento, R; Zancan, M | 1 |
| Andreetta, C; Banna, G; Battelli, N; Berardi, R; Bisagni, G; Boni, C; Bottini, A; Conte, P; Cresti, N; Di Blasio, B; Ficarra, G; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Maiorana, A; Michelotti, A; Piacentini, F; Puglisi, F; Santoro, A | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Deng, Z; Du, WW; Fang, L; Jeyapalan, Z; Seth, A; Shan, SW; Yang, BB; Yang, BL; Yee, AJ; Zhang, Y | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| Alba, E; Albanell, J; Barnadas, A; Burgués, O; Caballero, R; Calvo, L; Cámara, MC; Carrasco, E; de la Haba, J; Lluch, A; Porras, I; Ramos, M; Rojo, F; Sánchez-Rovira, P; Tibau, A | 1 |
| Bodmer, A; Bonnefoi, H; Brain, E; Cameron, D; Chakiba, C; Jacot, W; Jerusalem, G; Matos, E; Messina, CG; Moldovan, C; Petit, T; Quenel-Tueux, N; Saghatchian, M; Slaets, L; Tredan, O; Venat-Bouvet, L; Vuylsteke, P; Zaman, K | 1 |
| Bian, C; Dong, J; Hu, A; Jiang, L; Liang, Y; Liu, P; Wang, H; Zhou, X | 1 |
1 review(s) available for quinazolines and epirubicin
| Article | Year |
|---|---|
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
10 trial(s) available for quinazolines and epirubicin
| Article | Year |
|---|---|
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Digestive System Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 1999 |
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Thiophenes; Treatment Outcome | 2000 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Epirubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Thiophenes | 2004 |
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; ErbB Receptors; Female; Gefitinib; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2 | 2005 |
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Ki-67 Antigen; Neoplasm Staging; Paclitaxel; Patient Compliance; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
3 other study(ies) available for quinazolines and epirubicin
| Article | Year |
|---|---|
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy.
Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Green Fluorescent Proteins; Humans; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine; Taxoids; Tyrphostins; Versicans | 2011 |
Diagnostic accuracy of MR, CT, and ECT in the differentiation of neoplastic from nonneoplastic spine lesions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cisplatin; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Retrospective Studies; Spinal Neoplasms; Thiophenes; Tomography, X-Ray Computed; Young Adult | 2020 |